| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PanGen Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,300.00 |
| 52 Week High | ₩6,920.00 |
| 52 Week Low | ₩3,750.00 |
| Beta | 0.088 |
| 11 Month Change | -13.83% |
| 3 Month Change | -25.86% |
| 1 Year Change | -21.96% |
| 33 Year Change | -53.71% |
| 5 Year Change | -29.39% |
| Change since IPO | -80.72% |
Recent News & Updates
Shareholder Returns
| A222110 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 10.8% | 14.5% | 7.9% |
| 1Y | -22.0% | 30.5% | -0.5% |
Return vs Industry: A222110 underperformed the KR Biotechs industry which returned 30.5% over the past year.
Return vs Market: A222110 underperformed the KR Market which returned -0.5% over the past year.
Price Volatility
| A222110 volatility | |
|---|---|
| A222110 Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A222110's share price has been volatile over the past 3 months.
Volatility Over Time: A222110's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Jaeseung Yoon | www.pangen.com |
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, as well as technology transfer service.
PanGen Biotech Inc. Fundamentals Summary
| A222110 fundamental statistics | |
|---|---|
| Market cap | ₩49.08b |
| Earnings (TTM) | -₩3.13b |
| Revenue (TTM) | ₩10.06b |
4.9x
P/S Ratio-15.7x
P/E RatioIs A222110 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A222110 income statement (TTM) | |
|---|---|
| Revenue | ₩10.06b |
| Cost of Revenue | ₩7.65b |
| Gross Profit | ₩2.40b |
| Other Expenses | ₩5.53b |
| Earnings | -₩3.13b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -274.15 |
| Gross Margin | 23.90% |
| Net Profit Margin | -31.12% |
| Debt/Equity Ratio | 12.6% |
How did A222110 perform over the long term?
See historical performance and comparison